LEVEMIR (insulin detemir) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2005.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
LEVEMIR (insulin detemir) is a long-acting basal insulin analog administered via subcutaneous injection, approved by the FDA in June 2005. It is indicated for the treatment of diabetes mellitus in patients requiring insulin therapy. The drug works by mimicking endogenous insulin, binding to insulin receptors and facilitating glucose uptake in peripheral tissues. LEVEMIR represents a foundational basal insulin therapy option in the competitive insulin analog market, competing primarily against insulin glargine products and other long-acting insulins.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Worked on LEVEMIR at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$287M Medicare spend — this is a commercially significant brand
LEVEMIR creates demand for brand managers, medical science liaisons (MSLs), sales representatives, and payer relations specialists focused on basal insulin management and competitive positioning against LANTUS and emerging biosimilars. Professionals working on this product require expertise in insulin pharmacology, diabetes treatment algorithms, payer reimbursement, and managed care negotiations. Currently, there are zero open positions linked to this product in available job market data, reflecting the mature, stable nature of the franchise.